ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

1. MATERIALS AND METHODS Data regarding the diagnosis, management, and follow‐up
of carcinoid syndrome (CS) and carcinoid heart disease (CHD) were identified by searches …

Carcinoid heart disease (CHD) is a paraneoplastic cardiac manifestation occurring in
patients with carcinoid syndrome (CS) and advanced neuroendocrine malignancy. In about …

Carcinoid heart disease (CHD) is a severe complication of carcinoid syndrome (CS) found
primarily in patients with small intestine neuroendocrine neoplasms (SI-NENs). Patients who …

Early diagnosis of cardiovascular disease signs and continued medical therapy can lower
death rates and the number of afflicted people. As there are more occurrences of …

ESC and updated. The Task Force received its entire financial support from the ESC without
any involvement from the healthcare industry. The ESC CPG supervises and coordinates the …

Carcinoid heart disease (CHD) is a rare cardiac complication that occurs most commonly in
patients with advanced neuroendocrine tumors and is a known sequela of carcinoid …

In this issue of JACC: Case Reports, Luthra et al.(1) provide an important contribution,
illustrating the application of evolving percutaneous cardiac valve replacement techniques …

medycznej oraz dowodów dostępnych w momencie publikacji tego dokumentu. ESC nie
ponosi odpowiedzialności w przypadku jakichkolwiek sprzeczności Zastrzeżenie …

El objetivo de esta guía de la ESC es asistir a los profesionales de la salud en el
diagnóstico y manejo de los pacientes con miocardiopatías de acuerdo con la mejor …